---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-151215"
form_type: "8-K"
ticker: "KLRS"
cik: "0001754068"
company_name: "Kalaris Therapeutics, Inc."
filed_at: "2026-04-10T23:59:59+00:00"
generated_at: "2026-05-15T06:41:42.873141+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# CFO Matthew Gall resigns; CAO Brett Hagen takes over as principal financial officer

## Summary
- Matthew Gall resigned as CFO, effective April 14, 2026.
- Brett Hagen, Chief Accounting Officer since Jan 2019, will serve as principal financial officer.
- Hagen previously held finance roles at Eloxx Pharmaceuticals, Proteostasis Therapeutics, and BIND Therapeutics.
- No changes to Hagen’s compensatory plans or arrangements were disclosed.
- Resignation reason not stated; departure is effective April 14, 2026.

## SEC filing metadata
- accession: 0001193125-26-151215
- form_type: 8-K
- ticker: KLRS
- cik: 0001754068
- company_name: Kalaris Therapeutics, Inc.
- filed_at: 2026-04-10T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1754068/000119312526151215/0001193125-26-151215-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1754068/000119312526151215/d108368d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-151215
- JSON: https://secwatch.observer/filing/0001193125-26-151215.json
- Plain text: https://secwatch.observer/filing/0001193125-26-151215.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.